Verona Pharma Plc ADR’s recent filing unveils that its Chief Medical Officer Rickard Kathleen A. unloaded Company’s shares for reported $0.66 million on Mar 12 ’25. In the deal valued at $8.35 per share,79,264 shares were sold. As a result of this transaction, Rickard Kathleen A. now holds 2,608,976 shares worth roughly $140.62 million.
Then, KATHLEEN RICKARD bought 9,908 shares, generating $621,232 in total proceeds.
Before that, ZACCARDELLI DAVID sold 640,264 shares. Verona Pharma Plc ADR shares valued at $3,205,226 were divested by the President and CEO at a price of $5.01 per share. As a result of the transaction, ZACCARDELLI DAVID now holds 14,367,552 shares, worth roughly $774.41 million.
ROTH MKM initiated its Verona Pharma Plc ADR [VRNA] rating to a Buy in a research note published on January 10, 2025; the price target was $68. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who began to cover the stock in early October with a ‘”an Overweight”‘ rating.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock fall -7.21% to $53.90. Over the last five days, the stock has lost -14.04%. Verona Pharma Plc ADR shares have risen nearly 16.06% since the year began. Nevertheless, the stocks have risen 232.10% over the past one year. While a 52-week high of $70.40 was reached on 03/03/25, a 52-week low of $11.39 was recorded on 01/10/25. SMA at 50 days reached $62.52, while 200 days put it at $39.59.
Levels Of Support And Resistance For VRNA Stock
The 24-hour chart illustrates a support level at 52.39, which if violated will result in even more drops to 50.89. On the upside, there is a resistance level at 55.94. A further resistance level may holdings at 57.99. The Relative Strength Index (RSI) on the 14-day chart is 34.60, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -5.53, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 93.29%. Stochastics %K at 23.44% indicates the stock is a holding.
How much short interest is there in Verona Pharma Plc ADR?
A steep rise in short interest was recorded in Verona Pharma Plc ADR stocks on 2025-03-14, growing by 2.06 million shares to a total of 9.85 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 7.78 million shares. There was a rise of 20.96%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on August 26, 2022 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $31 price target.
